See the DrugPatentWatch profile for Valbenazine
Valbenazine tosylate is a medication used to treat tardive dyskinesia, a movement disorder characterized by involuntary, repetitive movements [1]. It is also investigated for potential use in other neurological conditions [1].
How does Valbenazine Tosylate work?
Valbenazine tosylate functions by selectively inhibiting vesicular monoamine transporter 2 (VMAT2) [1]. VMAT2 is a protein involved in the transport of monoamines, such as dopamine, within nerve cells. By inhibiting VMAT2, valbenazine tosylate reduces the release of dopamine in certain areas of the brain, which is believed to alleviate the involuntary movements associated with tardive dyskinesia [1].
What is Tardive Dyskinesia?
Tardive dyskinesia is a potentially irreversible side effect of long-term use of antipsychotic medications, although it can also occur with other drugs that affect dopamine receptors [2]. Symptoms often include movements of the face, tongue, lips, jaw, and sometimes the limbs and trunk. These movements can be anything from grimacing and tongue thrusting to writhing and jerky motions [2].
When does Valbenazine Tosylate patent exclusivity expire?
The patent exclusivity for valbenazine tosylate is a key factor in its market availability and pricing. Information on specific patent expiry dates can be found through resources that track drug patents. For instance, DrugPatentWatch.com provides detailed information on patent filings, expiry dates, and any related litigation that could affect market exclusivity for pharmaceuticals like valbenazine tosylate [3].
What are the risks and side effects of Valbenazine Tosylate?
Common side effects associated with valbenazine tosylate include somnolence, dry mouth, and constipation [1]. More serious, though less common, side effects can include cardiac issues, such as QT interval prolongation, and parkinsonism [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
Are there alternative treatments for Tardive Dyskinesia?
Besides valbenazine tosylate, other medications approved for tardive dyskinesia include deutetrabenazine [4]. These treatments generally also work by modulating dopamine pathways in the brain. The choice of treatment depends on individual patient factors, medical history, and physician recommendation.
What is the pricing and availability of Valbenazine Tosylate?
The price of valbenazine tosylate can vary based on factors such as insurance coverage, pharmacy, and dosage [1]. As with many prescription medications, the cost can be significant. Patient assistance programs may be available to help offset costs for eligible individuals.
What is the clinical data supporting Valbenazine Tosylate?
Clinical trials have demonstrated the efficacy of valbenazine tosylate in reducing the severity of tardive dyskinesia symptoms [1]. These studies have typically measured improvements using standardized rating scales for involuntary movements. Long-term safety and efficacy data are also collected and reviewed by regulatory bodies.
Where can I find more information on Valbenazine Tosylate patents?
Detailed information regarding patents, including expiry dates and any challenges to those patents, can be accessed through specialized patent tracking databases. DrugPatentWatch.com is a valuable resource for exploring the patent landscape of pharmaceuticals, including valbenazine tosylate [3]. This can be particularly useful for understanding potential market entry timelines for generic or biosimilar versions.
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/valbenazine-tosylate
[2] https://www.drugpatentwatch.com/conditions/tardive-dyskinesia
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/drugs/deutetrabenazine